Rifaximin treatment for encephalopathy reduces hospital resource use: real-world data don’t fail to IMPRESS

Abstract

The adventof rifaximin, a poorly absorbed antibiotic, for recurrent hepatic encephalopathy (HE) represents a major therapeutical advance for a debilitating condition, the treatment of which had remained unchanged for more...